Search

Your search keyword '"Mouret, A."' showing total 6,514 results

Search Constraints

Start Over You searched for: Author "Mouret, A." Remove constraint Author: "Mouret, A."
6,514 results on '"Mouret, A."'

Search Results

1. Terahertz Frequency Comb High-Resolution Heterodyne Spectrometer

2. Monitoring of food spoilage by high resolution THz analysis

3. Flying in air ducts

4. Tree species classification at the pixel-level using deep learning and multispectral time series in an imbalanced context

5. Words2Contact: Identifying Support Contacts from Verbal Instructions Using Foundation Models

6. Flow Matching Imitation Learning for Multi-Support Manipulation

7. Parametric-Task MAP-Elites

8. Multi-Contact Whole-Body Force Control for Position-Controlled Robots

9. Estimation of forest height and biomass from open-access multi-sensor satellite imagery and GEDI Lidar data: high-resolution maps of metropolitan France

10. Neoadjuvant and adjuvant pembrolizumab in advanced high-grade serous carcinoma: the randomized phase II NeoPembrOV clinical trial

11. Immunomic longitudinal profiling of the NeoPembrOv trial identifies drivers of immunoresistance in high-grade ovarian carcinoma

12. Feasibility Retargeting for Multi-contact Teleoperation and Physical Interaction

13. BOP-Elites, a Bayesian Optimisation Approach to Quality Diversity Search with Black-Box descriptor functions

14. Neoadjuvant anthracycline-based (5-FEC) or anthracycline-free (docetaxel/carboplatin) chemotherapy plus trastuzumab and pertuzmab in HER2 + BC patients according to their TOP2A: a multicentre, open-label, non-randomized phase II trial

15. Multi-Task Multi-Behavior MAP-Elites

16. Larger cities host richer bee faunas, but are no refuge for species with concerning conservation status: Empirical evidence from Western Europe

17. Neoadjuvant and adjuvant pembrolizumab in advanced high-grade serous carcinoma: the randomized phase II NeoPembrOV clinical trial

18. Immunomic longitudinal profiling of the NeoPembrOv trial identifies drivers of immunoresistance in high-grade ovarian carcinoma

19. Circulating immune landscape in melanoma patients undergoing anti-PD1 therapy reveals key immune features according to clinical response to treatment

20. Use of tamoxifene-controlled ovarian hyperstimulation for fertility preservation before breast cancer treatment: A prospective cohort study with a 5-year follow-up

22. The Use of Waste Polythene Sachet as Fiber in the Production of Concrete

23. Le strade per superare, visitare e proteggere le pareti rocciose. Questioni ambientali dello sviluppo infrastrutturale nelle Alpi francesi (secoli XIX-XXI)

24. Efficacy of subsequent therapies in patients with advanced ovarian cancer who relapse after first-line olaparib maintenance: results of the PAOLA-1/ENGOT-ov25 trial

25. Curcumin's effect in advanced and metastatic breast cancer patients treated with first or second‐line docetaxel: A randomized trial

34. PlantCoopLab, coopérer avec les plantes pour une alimentation durable

35. First do not fall: learning to exploit a wall with a damaged humanoid robot

36. Data-efficient learning of object-centric grasp preferences

37. A Robust and Flexible EM Algorithm for Mixtures of Elliptical Distributions with Missing Data

39. An Online Data-Driven Emergency-Response Method for Autonomous Agents in Unforeseen Situations

40. Reconstruction of Sentinel-2 Time Series Using Robust Gaussian Mixture Models -- Application to the Detection of Anomalous Crop Development in wheat and rapeseed crops

42. Larger cities host richer bee faunas, but are no refuge for species with concerning conservation status: Empirical evidence from Western Europe

43. The adaptor protein 2 (AP2) complex modulates habituation and behavioral selection across multiple pathways and time windows

44. Cancer Risks Associated With BRCA1 and BRCA2 Pathogenic Variants

46. Liaisons pastorales

48. VP-GO: a 'light' action-conditioned visual prediction model

49. Prescient teleoperation of humanoid robots

50. Prognostic value of EndoPredict test in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative primary breast cancer screened for the randomized, double-blind, phase III UNIRAD trial

Catalog

Books, media, physical & digital resources